Email this article Identification of gestosis (preeclampsia) risk and evaluation of efficiency of its prevention by means of noninvasive measurement of endothelial function
- Authors: Mozgovaya E.V.1, Postnikova T.B.2, Arzhanova O.N.1, Repinskaya E.A.3, Serdyukov S.V.4, Vinokurova N.V.3
-
Affiliations:
- D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS
- SPb Delivery Clinic N 10
- Saint Petersburg State University
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 64, No 3 (2015)
- Pages: 58-68
- Section: Articles
- URL: https://journals.rcsi.science/jowd/article/view/1253
- DOI: https://doi.org/10.17816/JOWD64358-68
- ID: 1253
Cite item
Full Text
Abstract
Research included 64 pregnants in the I trimester with adverse anamnesis and/or clinical risk factors of preeclampsia and with revealed endothelial dysfunction by means of the device EndoPat-2000, on the basis of the reactive hyperemia index (RHI) less than 1.67, which is automatically measured by the device. Before detection of endothelial dysfunction all pregnants received basic prevention of preeclampsia with preparations of multivitamins, magnesium and progesterone. At identification of decrease in RHI to 1.3 preparation Norvesol containing omega-3 polyunsaturated fat acids (1 group, n = 32) was added. And at RHI value less than 1,3 a preparation of Angiofllux - capsular sulodexide, containing fraction of heparin 7000 Da was added. At pregnants accepting Norvesol, RHI grew in the II trimester to 1.85 ± 0.28 (р > 0.05), and in the III trimester to 1.95 ± 0.19 (р < 0,05 in comparison with the first research). At pregnants accepting Angioflux in the II trimester RHI increased to 1.77 ± 0.25 (р < 0.05) and in III to 1.88 ± 0.20 (р ˂ 0.01 in comparison with the first research). No significant changes of indicators of system of hemostasis in dynamics were revealed in both groups. At all examined patients the delivery occurred at the full-term pregnancy. Frequency of preeclampsia development was low (21.9 and 37.5 % respectively in 1 and 2 groups), and except 1 case of middle severity in 1 group, preeclampsia didn’t exceed mild degree and didn’t influence a way of delivery and perinatal indicators. Thus, the method of functional endothelial state assessment by means of the device EndoPat-2000, allowed to specify risk degree of preeclampsia and to control efficiency of preventive therapy. At moderate violations of endothelial functional state Norvesol’s application led to correction of endothelial dysfunction and achievement of favorable outcomes of pregnancy and delivery for mother and fetus. At the cases with expressed endothelial dysfunction addition of Angioflux (sulodexide) promoted considerable improvement of endothelial function that allowed to avoid development of middle and severe preeclampsia even at pregnants with the highest risk of its development.
Full Text
##article.viewOnOriginalSite##About the authors
Elena Vital’yevna Mozgovaya
D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS
Email: elmozg@mail.ru
MD, leading scientific researcher, the head 3th department of pathology of pregnancy
Tat’yana Borisovna Postnikova
SPb Delivery Clinic N 10obstetrician-gynecologist.
Ol’ga Nikolaevna Arzhanova
D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS
Email: elmozg@mail.ru
MD, professor, the head of I department of pathology of pregnancy
Ekaterina Andreevna Repinskaya
Saint Petersburg State Universitystudent, graduate of magistracy of the Department of obstetrics, gynecology and reproductology, med. facult
Sergey Viktorovich Serdyukov
North-Western State Medical University named after I.I. Mechnikovassistant of the Department of hospital therapy and cardiology
Natal’ya Vladimirovna Vinokurova
Saint Petersburg State Universitypostgraduate student of the Department of obstetrics, gynecology and reproductology, med. facult.
References
- Айламазян Э. К., Мозговая Е. В. Гестоз: теория и практика. М.: МЕДпресс-информ, 2008; 272.
- Громова О. А., Торшин И. Ю., Лиманова О. А., Серов В. Н. О профилактической, лечебной и избыточной дозе омега-3 полиненасыщенных жирных кислот в прегравидарный период, во время беременности и кормления грудью. Эффективная фармакотерапия. Акушерство и гинекология». 2014; 4 (45).
- Кошелева Н. Г., Аржанова О. Н., Комаров Е. К. Применение препаратов магния при сочетанных формах гестоза, профилактика и лечение. Издательство: Н-Л, 2012; 36.
- Макацария А. Д., Мищенко А. Л., Бицадзе В. О., Маров С. В. Синдром диссеминированного внутрисосудистого свертывания крови. М.: Триада-Х, 2002; 496.
- Момот А. П., Баркаган З. С., Сердюк Г. В. Сулодексид и его применение в акушерской практике. Тромбоз гемостаз и реология. 2008; 1: 49-51.
- Мондоева С. С., Суханова Г. А., Подзолкова Н. М. Применение сулодексида в акушерской практике. Проблемы репродукции. 2008; 14: 2: 73-6.
- Ребров В. Г., Громова О. А. Витамины, макро- и микроэлементы. Изд-во: ГЭОТАР-Медиа. 2008; 960.
- Соколян А. В. Роль ангиогенных факторов роста в прогнозировании акушерской патологии у беременных: дис. канд. мед. наук: Москва, 2009; 139.
- Ходжаева З. С., Холин А. М., Вихляева Е. М. Ранняя и поздняя преэклампсия: парадигмы патобиологии и клиническая практика. Акуш. и Гин. 2013; 10: 4-11.
- Bernardi F., Guolo F., Bortolin T., Petronilho F., Dal-Pizzol F. Oxidative stress and inflammatory markers in normal pregnancy and preeclampsia. Journal of Obstetrics and Gynaecology Research. 2008: 34 (6): 948-51.
- Bonetti P. O, Pumper G. M., Higano S. T., Holmes D. R. Jr, Kuvin J. T., Lerman A. Research Highlights - editorial review of a noninvasive test for endothelial disfunction. Nature clinical Practice Cardiovascular Medicine. 2005; 2: 64-5.
- Demin G. S., Ivashchenko T. E., Mozgovaia E.V., Malysheva O.V., Baranov V. S. Association of some vascular genetic markers with different forms of preeclampsia. European Journal of Human Genetics. 2005; 13 (suppl. 1): 331-2.
- James J. L., Whitley G. S., Cartwright J. E. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. Journal of Pathology. 2010; 221 (4): 363-78.
- Nohria A., Gerhard-Herman H., Creager M. A., Hurley S., Mitra D., Ganz P. The role of Nitric Oxide in the regulation of digital pulse volume amplitude in humans. Appl. Physiol. 2002; 101: 545-8.
- Rodriguez M., Moreno J., Hasbun J. RAS in Pregnancy and Preeclampsia and Eclampsia//International Journal of Hypertension, Volume 2012 (2012), Article ID 739274, 6 pages.
- Schmidt M., Dogan C., Birdir C., Kuhn Ul., Gellhaus Al. Rainer, Kasimir-Bauer S.: Placental Growth Factor: A Predictive Marker for Preeclampsia? Gynakologisch-geburtshilfliche Rundschau. 2009; 49 (2): 94-9.
- Sibai B. M. Diagnosis, prevention, and management of eclampsia. Obstetrics and Gynecology. 2005: 105 (2): 402-10.
- Zainul Rashid M. R. et al. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol Endocrinol, 2014; 30 (3): 217-20.
Supplementary files
